Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis

Tuomainen, 1997, Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men, Diabetes Care, 20, 426, 10.2337/diacare.20.3.426

Conte, 1998, Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus, Ann Intern Med, 128, 370, 10.7326/0003-4819-128-5-199803010-00005

Fernandez-Real, 1998, Serum ferritin as a component of the insulin resistance syndrome, Diabetes Care, 21, 62, 10.2337/diacare.21.1.62

Kwan, 1998, Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene, Clin Invest Med, 21, 251

Fernandez-Real, 1999, C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes (letter), Diabetes Care, 22, 525, 10.2337/diacare.22.3.525

Perez de Nanclares, 2000, Excess iron storage in patients with type 2 diabetes unrelated to primary hemochromatosis, New Engl J Med, 343, 890

Sampson, 2000, Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes, J Lab Clin Med, 135, 170, 10.1067/mlc.2000.104464

Moczulski, 2001, Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy, Diabetes Care, 24, 1187, 10.2337/diacare.24.7.1187

Cavallo-Perin, 1995, Insulin resistance and hyperinsulinemia in homozygous β-thalassemia, Metabolism, 44, 281, 10.1016/0026-0495(95)90155-8

Hramiak, 1997, Factors affecting glucose tolerance in hereditary hemochromatosis, Clin Invest Med, 20, 110

Merkel, 1988, Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion, New Engl J Med, 318, 809, 10.1056/NEJM198803313181303

Mendler, 1999, Insulin resistance-associated hepatic iron overload, Gastroenterology, 117, 1155, 10.1016/S0016-5085(99)70401-4

Fargion, 2001, Hyperferritinemia, iron overload, and metabolic alterations identify patients at risk for nonalcoholic steatohepatitis, Am J Gastroenterol, 96, 2448, 10.1111/j.1572-0241.2001.04052.x

Facchini, 1998, Effect of phlebotomy on plasma glucose and insulin concentrations (letter), Diabetes Care, 21, 2190, 10.2337/diacare.21.12.2190b

Fernandez-Real, 2002, Blood letting in high-ferritin type 2 diabetes: effect on insulin sensitivity and beta-cell function, Diabetes, 51, 1000, 10.2337/diabetes.51.4.1000

Facchini, 2002, Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease, Gastroenterology, 122, 931, 10.1053/gast.2002.32403

Angulo, 2002, Nonalcoholic fatty liver disease, New Engl J Med, 346, 1221, 10.1056/NEJMra011775

Marchesini, 1999, Association of nonalcoholic fatty liver disease with insulin resistance, Am J Med, 107, 450, 10.1016/S0002-9343(99)00271-5

Marchesini, 2001, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844

Comert, 2001, Insulin resistance in non-alcoholic steatohepatitis, Dig Liver Dis, 33, 353, 10.1016/S1590-8658(01)80091-8

Valenti, 2002, Tumor necrosis factor α promoter polymorphism and insulin resistance in nonalcoholic fatty liver disease, Gastroenterology, 122, 274, 10.1053/gast.2002.31065

Knobler, 1999, Fatty liver—an additional and treatable feature of the insulin resistance syndrome, Q J Med, 92, 73, 10.1093/qjmed/92.2.73

Teli, 1995, The natural history of nonalcoholic fatty liver: a follow-up study, Hepatology, 22, 1714, 10.1002/hep.1840220616

Matteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8

Poonwala, 2000, Prevalence of obesity and diabetes in patients with cryptogenetic cirrhosis: a case-control study, Hepatology, 32, 689, 10.1053/jhep.2000.17894

Angulo, 1999, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 30, 1356, 10.1002/hep.510300604

Bonkovsky, 1999, Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis, J Hepatol, 31, 421, 10.1016/S0168-8278(99)80032-4

Chitturi, 2002, HFE mutations, hepatic iron, and fibrosis: ethnic specific association of NASH with C282Y but not with fibrotic severity, Hepatology, 36, 142, 10.1053/jhep.2002.33892

Sheth, 1997, Nonalcoholic steatohepatitis, Ann Intern Med, 126, 137, 10.7326/0003-4819-126-2-199701150-00008

Scheuer, 1962, Hepatic pathology in relatives of patients with hemochromatosis, J Pathol Bacteriol, 84, 53, 10.1002/path.1700840107

Barry, 1971, Measurement of liver iron concentration in needle biopsy specimens, Lancet, 1, 100, 10.1016/S0140-6736(71)90838-5

Haffner, 1997, The homeostasis model in the San Antonio heart study, Diabetes Care, 20, 1087, 10.2337/diacare.20.7.1087

Bonora, 2000, Homeostasis metabolic assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity, Diabetes Care, 23, 57, 10.2337/diacare.23.1.57

Sampietro, 1998, High prevalence of the His63Asp mutation in Italian patients with porphyria cutanea tarda, Hepatology, 27, 181, 10.1002/hep.510270128

Roff, 1989, The statistical analysis of mitochondrial DNA polymorphisms: chi square and the problem of small samples, Mol Biol Evol, 6, 539

Beutler, 1997, Genetic iron beyond hemochromatosis: clinical effects of HLA-H mutations, Lancet, 349, 296, 10.1016/S0140-6736(97)22005-2

Torti, 2002, Regulation of ferritin genes and protein, Blood, 99, 3505, 10.1182/blood.V99.10.3505

Dubois-Laforgue, 2000, Clinical characteristics of type 2 diabetes in patients with mutations of HFE, Diabetes Metab, 26, 65

Guillygomarc’h, 2001, Venesection therapy for insulin resistance associated hepatic iron overload, J Hepatol, 35, 344, 10.1016/S0168-8278(01)00147-7